Email: cspc@cspc.cn
News
News Center
Mar. 31
2026
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER
Mar. 20
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 16
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar. 05
VOLUNTARY ANNOUNCEMENT - INDACATEROL ACETATE AND MOMETASONE FUROATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 04
VOLUNTARY ANNOUNCEMENT - EMICIZUMAB INJECTION (SYS6053) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 02
VOLUNTARY ANNOUNCEMENT - PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) OBTAINS CLINICAL TRIAL APPR
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
